CAB + RPV — Competitive Intelligence Brief

CAB + RPV (CAB + RPV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor). Area: Infectious Disease / Virology.

phase 3 Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) HIV integrase and HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

CAB + RPV (CAB + RPV) — Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). CAB + RPV is a long-acting injectable combination of cabotegravir (an integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) that suppresses HIV replication by blocking two critical steps in the viral life cycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAB + RPV TARGET	CAB + RPV	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	phase 3	Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV integrase and HIV reverse transcriptase
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
Cabotegravir LA + Rilpivirine LA	Cabotegravir LA + Rilpivirine LA	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	marketed	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase
CAB LA + RPV LA	CAB LA + RPV LA	ViiV Healthcare	phase 3	Antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV integrase and HIV reverse transcriptase
Cabotegravir, Rilpivirine Drug Combination	Cabotegravir, Rilpivirine Drug Combination	University Paris 7 - Denis Diderot	phase 3	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
Dolutegravir + Lamivudine FDC	Dolutegravir + Lamivudine FDC	ViiV Healthcare	phase 3	Antiretroviral combination (INSTI + NRTI)	HIV integrase and HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) class)

1. Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 drug in this class